Danielle Antalffy
Stock Analyst at UBS
(3.46)
# 926
Out of 5,150 analysts
202
Total ratings
46.55%
Success rate
5.55%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXST RxSight | Maintains: Neutral | $8 → $9 | $7.62 | +18.11% | 5 | Feb 26, 2026 | |
| SYK Stryker | Maintains: Neutral | $386 → $400 | $384.59 | +4.01% | 7 | Feb 24, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $17 → $22 | $23.74 | -7.33% | 16 | Feb 20, 2026 | |
| ATRC AtriCure | Maintains: Buy | $60 → $55 | $31.46 | +74.83% | 14 | Feb 18, 2026 | |
| BSX Boston Scientific | Maintains: Buy | $140 → $120 | $73.85 | +62.49% | 15 | Feb 5, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Sell | $88 → $86 | $97.97 | -12.22% | 7 | Jan 28, 2026 | |
| EW Edwards Lifesciences | Maintains: Neutral | $92 → $95 | $85.28 | +11.40% | 14 | Jan 12, 2026 | |
| SGHT Sight Sciences | Maintains: Buy | $7 → $12 | $5.26 | +128.14% | 3 | Dec 23, 2025 | |
| INSP Inspire Medical Systems | Maintains: Neutral | $89 → $91 | $65.80 | +38.30% | 8 | Dec 23, 2025 | |
| GKOS Glaukos | Maintains: Buy | $140 → $145 | $117.75 | +23.14% | 3 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $62 | $26.26 | +136.10% | 4 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $102 | $96.71 | +5.47% | 12 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $355 → $400 | $241.84 | +65.40% | 13 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.5 → $5.85 | $1.57 | +272.61% | 8 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $16 | $13.60 | +17.65% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $95 | $73.08 | +29.99% | 10 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $21 | $19.03 | +10.35% | 7 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $585 → $600 | $497.42 | +20.62% | 3 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $190 → $214 | $246.75 | -13.27% | 6 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $57 | $25.29 | +125.39% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $146 → $148 | $113.61 | +30.27% | 12 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $3.68 | -38.86% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $3.48 | +23,606.90% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $29.83 | -53.07% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $78.84 | +26.84% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $13.83 | -13.23% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $34.39 | +30.85% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $174.21 | +57.86% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $2.87 | +596.86% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $6.21 | +576.33% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $60 | $6.83 | +779.12% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.80 | +1,775.00% | 1 | Sep 1, 2020 |
RxSight
Feb 26, 2026
Maintains: Neutral
Price Target: $8 → $9
Current: $7.62
Upside: +18.11%
Stryker
Feb 24, 2026
Maintains: Neutral
Price Target: $386 → $400
Current: $384.59
Upside: +4.01%
Tandem Diabetes Care
Feb 20, 2026
Maintains: Neutral
Price Target: $17 → $22
Current: $23.74
Upside: -7.33%
AtriCure
Feb 18, 2026
Maintains: Buy
Price Target: $60 → $55
Current: $31.46
Upside: +74.83%
Boston Scientific
Feb 5, 2026
Maintains: Buy
Price Target: $140 → $120
Current: $73.85
Upside: +62.49%
Zimmer Biomet Holdings
Jan 28, 2026
Maintains: Sell
Price Target: $88 → $86
Current: $97.97
Upside: -12.22%
Edwards Lifesciences
Jan 12, 2026
Maintains: Neutral
Price Target: $92 → $95
Current: $85.28
Upside: +11.40%
Sight Sciences
Dec 23, 2025
Maintains: Buy
Price Target: $7 → $12
Current: $5.26
Upside: +128.14%
Inspire Medical Systems
Dec 23, 2025
Maintains: Neutral
Price Target: $89 → $91
Current: $65.80
Upside: +38.30%
Glaukos
Dec 23, 2025
Maintains: Buy
Price Target: $140 → $145
Current: $117.75
Upside: +23.14%
Dec 12, 2025
Initiates: Buy
Price Target: $62
Current: $26.26
Upside: +136.10%
Nov 19, 2025
Maintains: Neutral
Price Target: $95 → $102
Current: $96.71
Upside: +5.47%
Nov 19, 2025
Upgrades: Buy
Price Target: $355 → $400
Current: $241.84
Upside: +65.40%
Nov 7, 2025
Maintains: Neutral
Price Target: $6.5 → $5.85
Current: $1.57
Upside: +272.61%
Nov 6, 2025
Maintains: Neutral
Price Target: $16 → $16
Current: $13.60
Upside: +17.65%
Nov 3, 2025
Maintains: Buy
Price Target: $106 → $95
Current: $73.08
Upside: +29.99%
Oct 31, 2025
Maintains: Neutral
Price Target: $24 → $21
Current: $19.03
Upside: +10.35%
Oct 23, 2025
Maintains: Neutral
Price Target: $585 → $600
Current: $497.42
Upside: +20.62%
Oct 14, 2025
Maintains: Buy
Price Target: $190 → $214
Current: $246.75
Upside: -13.27%
Aug 8, 2025
Maintains: Buy
Price Target: $65 → $57
Current: $25.29
Upside: +125.39%
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $113.61
Upside: +30.27%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $3.68
Upside: -38.86%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $3.48
Upside: +23,606.90%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $29.83
Upside: -53.07%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $78.84
Upside: +26.84%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $13.83
Upside: -13.23%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $34.39
Upside: +30.85%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $174.21
Upside: +57.86%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $2.87
Upside: +596.86%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $6.21
Upside: +576.33%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $60
Current: $6.83
Upside: +779.12%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $0.80
Upside: +1,775.00%